Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073879 · ClinicalTrials.gov registry record · NA
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
A NA study of Kidney Cancer, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 1
- Study location
NCT00073879: Completed NA study of Kidney Cancer, sponsored by Baylor College of Medicine.
NCT00073879 is a NA study of Kidney Cancer that has completed, run by Baylor College of Medicine. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00073879, a NA study of Kidney Cancer, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells can reject the body's normal tissues. Alemtuzumab and tacrolimus may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of combining fludarabine and cyclophosphamide with alemtuzumab in treating patients who are undergoing allogeneic stem cell transplantation for recurrent or metastatic renal cell carcinoma (kidney cancer).
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- BIOLOGICAL alemtuzumab
- PROCEDURE allogeneic bone marrow transplantation
- BIOLOGICAL graft-versus-tumor induction therapy
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-04 |
| Est. Completion | 2004-04 |
| Phase | NA |
What the finished NCT00073879 record still lists
NCT00073879 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00073879 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00073879 about?
NCT00073879 is a clinical study titled "Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation". RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted...
What is the current status of trial NCT00073879?
This trial is currently completed. It is a NA study. The study started on 2003-04. Estimated completion is 2004-04.
What conditions does trial NCT00073879 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT00073879?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), alemtuzumab (BIOLOGICAL), allogeneic bone marrow transplantation (PROCEDURE), graft-versus-tumor induction therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00073879?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00073879 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
RECRUITING · NA
-
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
RECRUITING · NA
-
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
RECRUITING · NA
-
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
RECRUITING · NA
-
Designing Visual Tools to Enhance Cancer Surgeon Decision-making
RECRUITING · NA
-
Integrated Actionable Aging Assessment for Cancer Patients Pilot
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia